NPPB and hydrops fetalis: Besides, the Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction (EMPIRE-HF) trial, which included 190 diabetic and non-diabetic patients, found no statistical significance in non-terminal prohormone B-type natriuretic peptide (NT-proBNP), QoL, or daily activity levels after providing EMPA 10 mg for three months [26].